United States
Print page content Print
Increase text size Decrease text size
Text Size
CYTOPOINT - now approved for the treatment of allergic dermatitis! Learn more

Discuss options and decide on treatment together

Discuss options and decide on treatment together

Talk to your client about 2 best-in-class options
for relief: CYTOPOINT and APOQUEL
(oclacitinib tablet) Cytopoint

  • With CYTOPOINT, a single in-office injection offers 4 to 8 weeks of relief,* giving damaged skin a chance to heal and helping to improve the quality of life for dogs
    and their families1
  • Both APOQUEL and CYTOPOINT have distinct advantages for relieving itch
  • These 2 options can also be used together to complement each other
CYTOPOINT—great for dogs... APOQUEL—great for dogs...
Under the age of 12 months Who need fast itch relief
Whose owners seek convenience of a 4-8 week treatment1 Whose owners find monthly office visits inconvenient
Who are difficult to pill Who are undergoing diagnostic tests
Who are left in the care of others (e.g., boarding) Whose owners prefer a daily tablet
Whose owners seek non-drug therapy Who are poorly controlled on other therapies
Who are on many other medications2 Whose owners are concerned about steroid side effects
Who are suboptimally controlled on APOQUEL Who have had flares while on another primary treatment
Who have comorbidities that preclude other therapies Who suffer from seasonal itch
Who require long-term management but receive APOQUEL when monthly veterinary visits are not possible2 Who experience flares or whose owner can't get to clinic for injection

When managing an atopic dermatitis patient, remember:

Treat for fleas year-round

Dogs with atopic dermatitis should be treated year-round for fleas3

Remain vigilant for infection

  • Up to 66 percent of dogs with atopic dermatitis have a concurrent yeast or bacterial skin infection4

Exeland's story5

  • 9-year-old male Labrador Retriever
  • Atopic dermatitis uncontrolled with antihistamines, glucocorticoids, cyclosporine, allergen-specific immunotherapy and elimination diet
  • Diagnosed with blastomycosis and treated with systemic antifungals, and secondary bacterial pneumonia and Staph pyoderma treated with systemic antibiotics
  • Exeland's veterinarian chose CYTOPOINT to manage the atopic dermatitis
  • 2 days after the initial injection, Exeland's owner reported that the itch was 0/10
  • Exeland's blastomycosis continues improving clinically and he remains free of skin and ear infections

CYTOPOINT helped protect the bond

Exeland's owner has a debilitating condition that affects his manual dexterity and makes regular pilling challenging, and Exeland's treatments and illness had been both mentally and physically overwhelming for him. For both owner and dog, Exeland's refractory itch had a severe negative impact on quality of life before CYTOPOINT.

CYTOPOINT Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL Important Safety Information: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

Repeat administration every 4 to 8 weeks as needed in individual patients.1

2015 ICADA Guidelines recommend systemic and oral adulticides like SIMPARICA for dogs who are frequently shampooed.

Common side effects of steroids include polyuria, polydipsia and polyphagia.6,7 Side effects of APOQUEL reported most often are vomiting and diarrhea.8

References: 1. Data on file, Study Report No. C863R-US-12-018, Zoetis LLC. 2. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc. 3. Olivry T, DeBoer D, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res. 2015;11:210. doi:10.1186/s12917-015-0514-6. 4. Bizikova P, Santoro D, Marsella R, et al. Review: clinical and histological manifestations of canine atopic dermatitis. Vet Dermatol. 2015;26(2):79-e24. 5. Data on file, CYTOPOINT Case Studies, 2015 Zoetis Inc. 6. Edwards SH. The Merck Veterinary Manual. 11th ed. Kenilworth, NJ: Merck Sharp & Dohme Corp; 2014. http://merckvetmanual.com/pharmacology/anti-inflammatory-agents/corticosteroids?qt=antiinflammatoryagents&alt=sh. Accessed January 4, 2018. 7. Sousa CA. Glucocosteroids in veterinary dermatology. In: Bonagura JD, Twedt DC, eds. Kirk’s Current Veterinary Therapy. 14th ed. St. Louis, MO: Saunders Elsevier; 2009:400-404. 8. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114. doi:10.1111/vde.12047.

The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2018 Zoetis Services LLC. All rights reserved ZPC-00064